Earnings Routine +

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Fennec Pharmaceuticals Q1 2026 Earnings

By The Northwire Desk — AI Analysis May 14, 2026 · 06:30 FRX · 9.28 FENNEC PHARMACEUTICALS INC. J

Executive Summary

Fennec Pharmaceuticals reported Q1 2026 net revenues of $15.1 million, a 73% increase year-over-year from $8.8 million in Q1 2025.
The company achieved a net income of $201,000 for the quarter, marking a turnaround from a net loss of $1.16 million in the same period last year.
Cash and cash equivalents increased to $40.2 million as of March 31, 2026, driven by operating cash flow of approximately $2.3 million and option exercises.
Research and Development expenses decreased to $49,000 compared to $94,000 in the prior year period.
Selling and Marketing Expenses rose significantly to $11.4 million from $3.2 million, reflecting commercialization efforts and sales force expansion.
General and Administrative (G&A) expenses decreased to $3.2 million from $5.9 million due to lower legal and professional fees.
A new institution-led clinical study was initiated by the University of Arizona Cancer Center for PEDMARK® in adolescent, young adult, and adult patients with head and neck and testicular cancers.
Four abstracts evaluating PEDMARK® were accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Material Impact

The Q1 2026 results validate the company's guidance provided in the transcript regarding positive cash flow and continued revenue growth, confirming the FY 2025 trend.
Achieving net income profit is a significant milestone following years of losses, though margins remain thin (approx. 1.3% net margin).
The 73% revenue growth rate exceeds the 50% full-year growth seen in FY 2025, indicating acceleration rather than deceleration.
The increase in Selling and Marketing expenses ($8.2M YoY) is consistent with management's stated strategy to expand commercial reach into the AYA market, which was guided as a priority for H1 2026.
Clinical updates (University of Arizona study and ASCO abstracts) are positive but incremental; they support long-term label expansion rather than immediate revenue realization.
The patent settlement with Cipla blocking generics until September 2033 remains the primary structural value driver, protecting this revenue stream.
Given the transcript explicitly stated an expectation for "positive cash flow in Q1 2026," this result is largely expected and priced into the recent trading range following the March earnings release.

FRX · Price

Company Overview

Company: Fennec Pharmaceuticals Inc. (NASDAQ: FRX / TSX: FRX).
Flagship Product: PEDMARK® (sodium thiosulfate injection).
Indication: FDA-approved to reduce cisplatin-induced ototoxicity in pediatric patients ≥1 month old with localized, non-metastatic solid tumors. NCCN 2A recommendation for adolescent and young adult (AYA) use.
Mechanism: Prevents hearing loss without compromising the antitumor efficacy of cisplatin chemotherapy.
Market Opportunity: Addressable AYA market estimated at >20,000 patients annually; total cisplatin-treated population is significantly larger.

More from FENNEC PHARMACEUTICALS INC. J